reports
Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 9:00 a.m. Pacific time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A webcast of the presentation will be available during the presentation in the Investors section of the company...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Inves...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to: http://www.zlk.com/mna/igny...
Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodula...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RXDX-106, a novel oral immunomodulatory agent and TAM inhibitor, in patients with solid tumors. Under this IND, the company intends to initiate the TITAN (Targeted Immunomodulatory TAM ANtagonist) study, a first-in-human, open label, multicenter, dose escalation s...
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investi...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to: http://www.zlk.com/mna/igny...
IGNYTA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Inves...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Ignyta, Inc. (NASDAQ CM: RXDX)? Did you purchase any of your shares prior to December 22, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) regarding possible...
Roche and Ignyta Reach Definitive Merger Agreement
SAN DIEGO--(BUSINESS WIRE)-- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 De...
Ignyta to Participate at the Global Mizuho Investor Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that it will participate in investor meetings at the Global Mizuho Investor Conference on December 5, 2017, in New York City. Investors who wish to meet with the Company’s management during this conference should contact the conference coordinator. About Ignyta, Inc. Blazing a New Future for Patients with Cancer™ At Ignyta, we work tirelessly on behalf o...
Ignyta to Present at the 29th Annual Piper Jaffray Healthcare Conferen...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017, at 11:00 a.m. local time (8:00 a.m. Pacific time) in New York City. A webcast of the presentation will be available during the presentation in the Investors section of the company's website at https://www.ignyta.com/inves...
Ignyta Reports Granting of Inducement Awards
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that it has issued two inducement awards to new non-executive employees. The awards were made on November 15, 2017, under Ignyta’s 2017 Employment Inducement Equity Incentive Award Plan, which was adopted on August 17, 2017, and provides for the granting of equity awards to new employees of Ignyta. The inducement awards were not individually negotiated and consist of options to purchase ...
Ignyta to Present at the Jefferies 2017 London Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Jefferies 2017 London Healthcare Conference on November 16, 2017, at 1:20 p.m. local time (5:20 a.m. Pacific time) in London, UK. A webcast of the presentation will be available during the presentation in the Investors section of the company's website at https://www.ignyta.com/investors/, and will be ar...
Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 a...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced new preclinical data for RXDX-106 – a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition. In the TME, TAM RTKs contribute to cancer cell evasion of the immune system and progression by promoti...
Ignyta Announces Third Quarter 2017 Company Highlights and Financial R...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the third quarter ended September 30, 2017. The company is issuing this press release in lieu of conducting a conference call. “We are pleased with the continued development and regulatory progress of our lead product candidate, entrectinib—an investigational, CNS-active, potent, and selective tyrosine kinase inhibitor being deve...
Ignyta to Present at Credit Suisse 26th Annual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at 11:35 a.m. Mountain time (10:35 a.m. Pacific time) in Scottsdale, AZ. A webcast of the presentation will be available during the presentation in the Investors section of the company's website at https://www.ignyta.com/inv...
Ignyta Announces Pricing of Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $16.00 per share. The gross proceeds from this offering are expected to be $160.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Ignyta. The offering is expected to close on or about October 24, 2017, subj...
Ignyta Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. In connection with this offering, Ignyta expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other...
Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the STARTRK-2 trial, of entrectinib - an investigational, CNS-active, potent, and selective tyrosine kinase inhibitor being developed for tumors that harbor NTRK fusions or ROS1 fusions. In this interim analysis, entrectinib demonstrated a 78% confirmed ORR (by Investigator; 95% CI: 60.0, 90.7) and a 69% confirmed ORR (by Bl...
Ignyta Receives European Medicines Agency Prime Designation for Entrec...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation for entrectinib in the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapy. Through the PRIME initiative, Ignyta will have enhanced EMA ...
Ignyta Reports Granting of Inducement Awards
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that it has issued four inducement awards to new non-executive employees. The awards were made on October 15, 2017, under Ignyta’s 2017 Employment Inducement Equity Incentive Award Plan, which was adopted August 17, 2017, and provides for the granting of equity awards to new employees of Ignyta. The inducement awards were not individually negotiated and consist of options to purchase an ...
Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of ...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced new preclinical data for RXDX-106 – a novel immunomodulatory agent with potent anti-tumor activity, alone and in combination with checkpoint inhibitors, that appears to restore and enhance overall immune function by reversing immunosuppression of innate immune cells in the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition. The data wer...
Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Prese...
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated data on entrectinib – an investigational, CNS-active, potent and selective tyrosine kinase inhibitor being developed in tumors that harbor NTRK fusions or ROS1 fusions — will be presented at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan on October 18, 2017. The oral presentation (abstract ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.